Paper Details

  1. Home
  2. Paper Details

Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan.

Author: AirolaGisella, AllaisGianni, BenedettoChiara, BorgognoPaola, BussoneGennaro, De LorenzoCristina, GabellariIlaria Castagnoli, PaviaElena

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Oral contraceptive-induced menstrual migraine (OCMM) is a type of migraine that is triggered by the cyclic pill suspension. This study investigated the efficacy of frovatriptan, a migraine medication, in the treatment of OCMM.
Paper Details　
Original Abstract of the Article :
Oral contraceptive-induced menstrual migraine (OCMM) is a poorly defined migraine subtype mainly triggered by the cyclic pill suspension. In this pilot, open-label trial we describe its clinical features and evaluate the efficacy of frovatriptan in the treatment of its acute attack. During the first...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10072-008-0921-6

データ提供：米国国立医学図書館（NLM）

Oral Contraceptive-Induced Menstrual Migraine

This pilot, open-label trial examines the clinical features of oral contraceptive-induced menstrual migraine (OCMM), a migraine subtype specifically triggered by the pill suspension. The researchers investigated the characteristics of OCMM and evaluated the efficacy of frovatriptan, a triptan medication used to treat migraine headaches, in managing acute OCMM attacks. Their objective was to shed light on the clinical characteristics of OCMM and explore a potential treatment option.

OCMM: A Unique Challenge in Migraine Management

The study's findings highlight the distinct characteristics of OCMM, with most attacks occurring within the first 5 days after pill suspension. Frovatriptan was found to be effective in reducing headache intensity and frequency in OCMM patients, offering a potential therapeutic option for managing acute attacks.

Navigating the Desert of Migraine: Finding Relief in Frovatriptan

Imagine a desert traveler searching for a cool oasis of relief during a searing migraine. This study offers a potential respite in the form of frovatriptan, a medication that can help alleviate the pain and discomfort associated with OCMM. However, further research is needed to determine the long-term effectiveness and optimal use of frovatriptan for managing OCMM.

Dr.Camel's Conclusion

This pilot trial provides valuable insights into the clinical features and potential treatment options for oral contraceptive-induced menstrual migraine. The study suggests that frovatriptan may be effective in managing acute OCMM attacks, highlighting the need for further research to explore its long-term efficacy and optimal use in this specific migraine subtype.

Date :
  1. Date Completed 2008-09-24
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

18545931

DOI: Digital Object Identifier

10.1007/s10072-008-0921-6

Related Literature

Article Analysis
・Effects of frovatriptan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.